Clinical trial
SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients
Abstract
SPL026 (N,N-dimethyltryptamine \[DMT\] fumarate) is a psychedelic tryptamine being developed as a therapy for patients with major depressive disorder (MDD).
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
This study's objects
Directly linked records, matched by DOI, trial reference, or registry, not just topic.
Publications from this trial
ArticleDMT
Pharmacokinetics of N,N-dimethyltryptamine in Humans.
ArticleDMT
Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial.
ArticleDMT
Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.
ArticleDMT
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.
Related research
ArticleDMT
Beyond the toad's kiss: Mapping acute 5-MeO-DMT effects on brain connectivity across sex and dose using awake rat neuroimaging.
ArticlePsilocybin
Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.
ArticlePsilocybin